Suramin ameliorates collagen induced arthritis

Suramin, a polysulfonated polyaromatic symmetrical urea is known for multiple therapeutic effects including antineoplastic activity. It is known as an antagonist of ATP at P2X purinergic receptors. Suramin is also found to inhibit protein synthesis affecting both initiation and elongation of the polypeptide chain. As a growth factor blocker, it is reported to suppress experimental myocardial inflammation. Here, we describe the anti-arthritic property of suramin in the collagen induced arthritic (CIA) rat, a model of human rheumatoid arthritis (RA). Intraperitoneal (i.p) injection of suramin (10 mg/kg/day) for 3 weeks was found to reduce inflammation and repair joint destruction in CIA rats. Recovery of body weight (p < 0.0001), reduction in splenic (p < 0.05) and arthritic indices (p < 0.0001) and reappearance of smooth synovial lining after suramin treatment to CIA rats were found to be significant. Levels of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 in plasma and joint extracts were reduced (p < 0.0001) significantly in response to suramin treatment. Several acute phase proteins were normalized after suramin administration.

► We developed a collagen induced arthritic (CIA) model of rheumatoid arthritis.
► Suramin (10 mg/kg) was found to ameliorate arthritis as evaluated using many parameters.
► Suramin reduced overall inflammation, joint damage, and pro-inflammatory cytokines.
► Acute phase proteins came to normal levels after suramin treatment.